文献速递先天性心脏病外科心外重症与机械循环支持

搏动性心室辅助装置作为高危单心室生理患儿早期心脏移植桥接

Pulsatile ventricular assist device as a bridge to transplant for the early high-risk single-ventricle physiology.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-10-06

单中心回顾性分析9例单心室生理患儿在第一阶段姑息手术前后植入Berlin Heart EXCOR搏动性心室辅助装置,移植桥接组出院生存率83%(5/6),决策桥接组33%(1/3),无重大中枢神经系统并发症(除1例显著出血事件),提示该策略在高危单心室围第一阶段期可行。

要点

  • 搏动性心室辅助装置可作为高危单心室生理患儿围第一阶段期的移植桥接选择
  • 移植桥接组出院生存率83%(5/6),决策桥接组33%(1/3)
  • 幸存者随访儿童总体表现类别评分为正常至轻度残疾者占83%

核心结论

  • 搏动性体外心室辅助装置作为围第一阶段期高危单心室生理患儿的移植桥接是可行选择。

研究设计与样本

  • 单中心回顾性综述,纳入植入Berlin Heart EXCOR心室辅助装置的单心室患者9例。
  • 中心策略包括早期植入、共同心房插管、心脏指数3.5–5 L/min/m2及基于比伐芦定的抗凝方案。

主要发现

  • 移植桥接组出院生存率为83%(5/6),决策桥接组为33%(1/3)。
  • 6例患者既往未接受姑息手术。
  • 非幸存者植入前中位住院时间为111天,幸存者为20天。
  • 非幸存者与幸存者需要体外膜氧合分别为3例中1例与6例中1例,需要心肺复苏分别为3例中2例与6例中1例。
  • 除1例显著出血事件外,无重大中枢神经系统并发症;幸存者随访儿童总体表现类别评分为正常至轻度残疾者占83%。

关键数值与推荐

  • 心脏指数维持在3.5–5 L/min/m2。
  • 抗凝采用基于比伐芦定的方案。
  • 植入后第1周及第1、2、3个月收集患者相关数据。

临床怎么用

  • 对围第一阶段期高危单心室生理患儿可考虑早期植入搏动性体外心室辅助装置作为移植桥接。
  • 采用共同心房插管、目标心脏指数3.5–5 L/min/m2及基于比伐芦定的抗凝方案。

局限性

  • 存在溶血及间歇性感染和/或炎症期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of ventricular assist devices (VADs) as a bridge-to-transplant in patients with single-ventricle physiology post-stage one palliation has been associated with poor outcomes. We describe our center's successful experience in the use of paracorporeal pulsatile VADs in the palliation of high-risk single ventricle physiology before or after the first stage of palliation with an impetus on pre-palliation implant. METHODS: This is a single-center retrospective review of univentricular patients implanted with the Berlin Heart EXCOR VAD. Our center's approach includes early implantation of the Berlin Heart EXCOR with common atrial cannulation, a cardiac index between 3.5 and 5 L/min/m2, and a bivalirudin-based anticoagulation regimen. Patient-related data were collected postimplant at week 1 and months 1, 2, and 3. Post-transplant data, including neurological outcomes, were collected. RESULTS: Nine patients were supported. Survival to discharge post-transplant was 83% (5/6) in patients bridged-to-transplant and 33% (1/3) in patients bridged-to-decision. Six patients had no previous palliation. Median hospital stay before implantation was 111 days for nonsurvivors versus 20 days for survivors. The need for extracorporeal membrane oxygenation and cardiopulmonary resuscitation in nonsurvivors versus survivors was 1 in 3 versus 1 in 6 and 2 in 3 versus 1 in 6, respectively. There were no major central nervous system complications except for 1 significant hemorrhagic event. The pediatric overall performance category score on follow-up was normal to mild disability in 83% of survivors. Limitations include hemolysis and intermittent periods of infection and/or inflammation. CONCLUSIONS: The use of pulsatile paracorporeal VADs is a feasible option as a bridge-to-transplant in the peri-stage one high-risk single ventricle.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Philip J, Powers E, Machado D, et al. Pulsatile ventricular assist device as a bridge to transplant for the early high-risk single-ventricle physiology. J Thorac Cardiovasc Surg. 2020. PMID: 33546851. doi:10.1016/j.jtcvs.2020.09.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。